MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Harvard Bioscience Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

0.59 5.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.56

Max

0.59

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.1M

-1.2M

Pardavimai

141K

21M

Pelno marža

-5.978

Darbuotojai

330

EBITDA

1M

1.2M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+244.83% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

616K

26M

Ankstesnė atidarymo kaina

-4.77

Ankstesnė uždarymo kaina

0.59

Naujienos nuotaikos

By Acuity

26%

74%

71 / 360 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Harvard Bioscience Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-21 23:49; UTC

Pagrindinės rinkos jėgos

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026-01-21 21:12; UTC

Pagrindinės rinkos jėgos

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 21:00; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026-01-21 20:29; UTC

Pagrindinės rinkos jėgos

Chip Makers Gain After Trump Calls Off European Tariffs

2026-01-21 20:04; UTC

Pagrindinės rinkos jėgos

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026-01-21 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026-01-21 23:34; UTC

Rinkos pokalbiai

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026-01-21 22:39; UTC

Uždarbis

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026-01-21 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-21 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-21 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026-01-21 21:19; UTC

Uždarbis

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026-01-21 20:45; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026-01-21 20:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026-01-21 20:31; UTC

Rinkos pokalbiai

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026-01-21 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026-01-21 20:27; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-21 20:27; UTC

Rinkos pokalbiai

Was It a 'TACO' Event? -- Market Talk

2026-01-21 20:26; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026-01-21 20:23; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026-01-21 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026-01-21 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse Group Agrees to Buy Allfunds

2026-01-21 20:08; UTC

Uždarbis

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026-01-21 20:03; UTC

Rinkos pokalbiai

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026-01-21 19:51; UTC

Rinkos pokalbiai

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026-01-21 19:43; UTC

Rinkos pokalbiai

U.S. Ethanol Production Expected to Slip -- Market Talk

2026-01-21 19:31; UTC

Rinkos pokalbiai

Gold Settles at Fresh All-Time High -- Market Talk

2026-01-21 19:24; UTC

Uždarbis

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026-01-21 19:10; UTC

Rinkos pokalbiai

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026-01-21 18:57; UTC

Rinkos pokalbiai

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harvard Bioscience Inc Prognozė

Kainos tikslas

By TipRanks

244.83% į viršų

12 mėnesių prognozė

Vidutinis 2 USD  244.83%

Aukščiausias 2 USD

Žemiausias 2 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harvard Bioscience Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.3 / 0.3401Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

No Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

71 / 360 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat